The modulation of IFN signalling in ErbB-2-overexpressing breast cancers warrants further investigation, and may possibly identify new therapy targets, and/or allow optimisation of current therapies that utilise IFNs to treat patients with cancer (Tossing, 2001). This evidence concerns the gene ERBB2 and breast carcinoma.